Associated tags: HER2, Engineering, Patient, Conjugation, Drug development, Zymeworks, Pharmaceutical industry, Research, Biotechnology
Locations: NEW YORK, CALIFORNIA, SAN FRANCISCO, ASIA, APAC, SINGAPORE, NY, FL, NV, MA, BENCHMARK, CHINA, ITALY, TD, CA, LOS ANGELES, TEL AVIV, PARIS, MIDDLETOWN, DE, US, BRITISH COLUMBIA, NORTH AMERICA, EUROPE, UNITED STATES, CHICAGO, LONDON
Retrieved on:
Thursday, August 10, 2023
Docetaxel,
GEA,
Abstract,
Partnership,
Therapy,
Senior,
BeiGene,
DOR,
ESMO,
Calendar,
Quality of life,
GAAP,
Research,
EDT,
PFS,
Public expenditure,
Congress,
Patient,
Cancer,
Corr,
Item,
ADC,
Spacecraft,
BTC,
Ovarian cancer,
IND,
Regulation S-K,
Regulation,
Sodium-dependent phosphate transport protein 2B,
Tislelizumab,
Pharmaceutical industry,
Medical imaging,
Management,
Cryptocurrency,
Life insurance,
Zymeworks,
Jazz,
The Lancet “During the second quarter of 2023, we made excellent progress in advancing several of our key planned corporate goals for the year,” said Kenneth Galbraith, Chair, President and Chief Executive Officer of Zymeworks.
Key Points:
- “During the second quarter of 2023, we made excellent progress in advancing several of our key planned corporate goals for the year,” said Kenneth Galbraith, Chair, President and Chief Executive Officer of Zymeworks.
- In partnership with Jazz and BeiGene, multiple abstracts for zanidatamab were presented at the ASCO Annual Meeting in Chicago in June 2023.
- Financial Results for the Six Months Ended June 30, 2023
Revenue for the six months ended June 30, 2023 was $42.6 million compared to $7.4 million for the same period of 2022.
- Reconciliations between historical GAAP and non-GAAP information are contained at the end of this press release following the accompanying financial data.
Wells Fargo Healthcare Conference: Zymeworks’ management will participate in one-on-one meetings and a fireside chat on September 7th – 8th in Boston, MA.
Key Points:
- Wells Fargo Healthcare Conference: Zymeworks’ management will participate in one-on-one meetings and a fireside chat on September 7th – 8th in Boston, MA.
- H.C. Wainwright 25th Annual Global Investment Conference: Zymeworks’ management will participate in one-on-one meetings and present on September 11th in New York, NY.
- Morgan Stanley’s 21st Annual Global Healthcare Conference: Zymeworks’ management will participate in one-on-one meetings and a fireside chat on September 12th in New York, NY.
- Cantor Global Healthcare Conference: Zymeworks’ management will participate in one-on-one meetings and a fireside chat on September 27th in New York, NY.
VANCOUVER, British Columbia, July 19, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will report its second quarter 2023 financial results after market close on August 10, 2023.
Key Points:
- VANCOUVER, British Columbia, July 19, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will report its second quarter 2023 financial results after market close on August 10, 2023.
- Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on August 10, 2023 at 4:30 p.m. Eastern Time (ET).
VANCOUVER, British Columbia, July 03, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conference:
Key Points:
- VANCOUVER, British Columbia, July 03, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conference:
BTIG Virtual Biotechnology Conference 2023: Zymeworks’ management will participate in one-on-one meetings on Aug 7– 8
Lundbeck Seattle Biopharmaceuticals,
Lundbeck,
Culture,
Allergan,
Eptinezumab,
Eli Lilly,
Organization,
Acquisition,
Patient,
Cancer,
Eli Lilly and Company,
Therapy,
Management,
Zymeworks,
Indiana University Mr. Campoy brings extensive strategic and financial leadership experience in the pharmaceutical and biotechnology sectors to the Zymeworks board of directors.
Key Points:
- Mr. Campoy brings extensive strategic and financial leadership experience in the pharmaceutical and biotechnology sectors to the Zymeworks board of directors.
- Mr. Campoy succeeds Dr. Natalie Sacks, who will step down effective as of June 30 after a successful 6-year tenure as board director of Zymeworks.
- “The entire Zymeworks’ board of directors and employees are sincerely grateful to Dr. Sacks for her dedicated service to Zymeworks.
- Egon Zehnder, a global leadership advisory firm, was actively engaged with Zymeworks in an advisory capacity and assisted in the recruitment of Mr. Campoy to the Zymeworks’ board of directors.
VANCOUVER, British Columbia, June 26, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that it is set to join both the Russell 3000®, Russell 2000®, and the Russell Microcap® Indexes at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the U.S. market opens on June 26, 2023.
Key Points:
- VANCOUVER, British Columbia, June 26, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that it is set to join both the Russell 3000®, Russell 2000®, and the Russell Microcap® Indexes at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the U.S. market opens on June 26, 2023.
- The annual reconstitution of the Russell indexes captures the 4,000 largest U.S. stocks as of April 28, 2023, ranking them by total market capitalization.
- FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.
- Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies.
Start-Up,
Biotechnology,
Professional Services,
Health,
General Health,
Pharmaceutical,
Oncology,
Other Science,
Research,
Science,
Clinical Trials,
Vaccine,
Workforce,
BIO,
Partnership,
Therapy,
Chronic kidney disease,
Diabetes,
Nephrology,
COVID-19,
GTA,
BIOTECanada,
Booth,
Cancer,
Breast,
Federal,
RNA,
AstraZeneca,
DSM-IV codes,
AbCellera,
Government,
Thought,
Lung,
Canadian Pavilion,
Hospital,
Investment,
Patient,
Indians of Canada Pavilion,
Ophthalmology,
Novo Nordisk,
Hematology,
Greater Toronto Area,
R,
Neurology,
Pharmaceutical industry The Canada booth at BIO2023 is a showcase of biopharma accomplishment and forward thinking towards creating the most welcoming and productive biopharma environment in the world.
Key Points:
- The Canada booth at BIO2023 is a showcase of biopharma accomplishment and forward thinking towards creating the most welcoming and productive biopharma environment in the world.
- “Starting with an emphasis on building our domestic capacity to develop and produce vaccines and therapeutics, we enacted ways to prepare Canada for the next biopharma challenges.
- More than 1,000 convention attendees from Canada will help showcase the nation’s advantages as a leading biopharma industry destination.
- The Canada Pavilion at BIO 2023 is located at Booth 2149 and will be staffed with senior trade representatives throughout the convention.
Neoplasm,
KOL,
ICR,
Progression-free survival,
HER2,
DOR,
American Society of Clinical Oncology,
RECIST,
Research,
Gallbladder cancer,
PFS,
IHC,
ASCO,
The Lancet,
University,
Annual general meeting,
Corr,
Kaplan–Meier estimator,
In situ hybridization,
Immunohistochemistry,
Jazz Pharmaceuticals,
BTC,
Therapy,
Society,
ORR,
Safety,
Disease,
Nursing,
Medical imaging,
Pharmaceutical industry,
Patient DUBLIN and VANCOUVER, BC, June 3, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Zymeworks Inc. (Nasdaq: ZYME) today presented positive pivotal trial data, including new data on progression-free survival (PFS), from the Phase 2b HERIZON-BTC-01 trial of the bispecific antibody zanidatamab in previously treated HER2-amplified biliary tract cancers (BTC). The data were featured as an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, and the results were concurrently published in The Lancet Oncology. The abstract (4008) was also selected to be included in the 2023 Best of ASCO® program, which will be held this summer following the ASCO Annual Meeting.
Key Points:
- The data were featured as an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, and the results were concurrently published in The Lancet Oncology .
- The abstract (4008) was also selected to be included in the 2023 Best of ASCO® program, which will be held this summer following the ASCO Annual Meeting.
- The KM estimated median PFS was 5.5 months [95% CI: 3.7, 7.2] with a range of 0.3 to 18.5 months.
- Results of the pivotal HERIZON-BTC-01 trial (NCT04466891) indicate that the HER2-targeted, bispecific antibody zanidatamab demonstrates rapid, durable responses with a manageable safety profile in patients with treatment-refractory HER2-amplified BTC.
Neoplasm,
KOL,
ICR,
Progression-free survival,
HER2,
DOR,
American Society of Clinical Oncology,
RECIST,
Research,
Gallbladder cancer,
PFS,
IHC,
ASCO,
The Lancet,
University,
Annual general meeting,
Corr,
Kaplan–Meier estimator,
In situ hybridization,
Immunohistochemistry,
Jazz Pharmaceuticals,
BTC,
Therapy,
Society,
ORR,
Safety,
Disease,
Nursing,
Medical imaging,
Pharmaceutical industry,
Patient DUBLIN and VANCOUVER, BC, June 2, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Zymeworks Inc. (Nasdaq: ZYME) today presented positive pivotal trial data, including new data on progression-free survival (PFS), from the Phase 2b HERIZON-BTC-01 trial of the bispecific antibody zanidatamab in previously treated HER2-amplified biliary tract cancers (BTC). The data were featured as an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, and the results were concurrently published in The Lancet Oncology. The abstract (4008) was also selected to be included in the 2023 Best of ASCO® program, which will be held this summer following the ASCO Annual Meeting.
Key Points:
- The data were featured as an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, and the results were concurrently published in The Lancet Oncology .
- The abstract (4008) was also selected to be included in the 2023 Best of ASCO® program, which will be held this summer following the ASCO Annual Meeting.
- The KM estimated median PFS was 5.5 months [95% CI: 3.7, 7.2] with a range of 0.3 to 18.5 months.
- Results of the pivotal HERIZON-BTC-01 trial (NCT04466891) indicate that the HER2-targeted, bispecific antibody zanidatamab demonstrates rapid, durable responses with a manageable safety profile in patients with treatment-refractory HER2-amplified BTC.
VANCOUVER, British Columbia, June 01, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences:
Key Points:
- VANCOUVER, British Columbia, June 01, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences:
Jefferies Global Healthcare Conference: Zymeworks’ management will participate in one-on-one meetings and present on June 8 at 1:00 pm Eastern Daylight Time (EDT) in New York, NY.
- Citi’s European Healthcare Conference: Zymeworks’ management will participate in one-on-one meetings on June 20-21 in London, UK.
